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Introduction
Gliomas are the most frequently diagnosed primary intracra-
nial, intraparenchymal neoplasm.1 Glioblastoma (GBM), the 
most common glioma histopathology (≈45% of all gliomas), is 
an aggressive malignancy with a 5-year relative survival of only 
≈5%, despite extensive ongoing research into surgical, chemo-
therapy, and radiological treatments. However, brain metasta-
ses from other primary sites are the most common intracranial 
malignancies in adults, with an incidence of more than 
170 000 per year in the US alone.2 By some estimates, more 
than 40% of cancer patients develop brain metastases, includ-
ing up to 50% of patients with lung cancer, >25% of patients 
with breast cancer, and 20% of patients with melanoma.2
Cytokines and chemokines constitute a growing group of 
small (<40 kDa) secreted bioactive proteins that perform 
diverse interactive roles in molecular communication between 
cells and tissues.3,4 The balanced release of various cytokines is 
important for maintaining normal homeostasis, and is also an 
essential component of a well-regulated immune response that 
changes in diverse disease states including cancers such as 
GBM.5-7 Developing profiles of multiple interacting bio-
markers in human plasma may have important utility in dif-
ferentially diagnosing and staging both primary and secondary 
intracranial tumors, tracking disease progression, estimating 
prognosis, and selecting optimal management strategies and 
following treatment responses.8-10
Multiplex immunoassays employ a variety of technologies, 
including planar chemiluminescence and bead-based immuno-
capture suspension array platforms, to simultaneously quantify 
circulating levels of many cytokines and other biomarkers.11 
These approaches are useful for deciphering the complex 
underlying biochemical mechanisms and interactions that 
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ABSTRACT: We compared the performance of two 96-well multiplex immunoassay platforms in assessing plasma cytokine concentrations in 
patients with glioblastoma (GBM; n = 27), individuals with melanoma, breast or lung cancer metastases to the brain (n = 17), and healthy volun-
teers (n = 11). Assays included a bead-based fluorescence MILLIPLEX® assay/Luminex (LMX) platform and 4 planar electrochemiluminescence 
kits from Meso Scale Discovery (MSD). The LMX kit evaluated 21 cytokines and the 3 MSD kits evaluated 20 cytokines in total, with 19 overlap-
ping human cytokines between platforms (GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-21, IL-23, MIP-
1α, MIP-1β, MIP-3α, TNFα). The MSD platform had lower LLoQs (lower limits of quantification) than LMX for 17/19 cytokines, and higher LLoQs 
for IFN-γ and IL-21. The ULoQs were higher in LMX versus MSD assays for 17/19 shared analytes, but lower than MSD for IL-17A and IL-21. 
With LMX, all 19 shared analytes were quantifiable in each of 55 samples. Although MSD recombinant protein standard curves indicated lower 
LLoQs than LMX for most cytokines, MSD detected 7/19 (37%) native analytes in <75% of samples, including 0% detection for IL-21 and 8% 
for IL-23. The LMX platform categorized identical samples at greater concentrations than the MSD system for most analytes (MIP-1β the sole 
exception), sometimes by orders of magnitude. This mismatched quantification paradigm was supported by Bland-Altman analysis. LMX identi-
fied significantly elevated levels of 10 of 19 circulating cytokines in GBM: GM-CSF, IFN-γ, IL-1β, IL-5, IL-10, IL-17A, IL-21, IL-23, MIP-1α, and 
MIP-3α, consistent with prior findings and confirming the utility of applying appropriate multiplex immunoassay technologies toward developing 
a cytokine signature profile for GBM.
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occur during many disease states, have great possibilities for 
accelerating epidemiological research, and are emerging as val-
uable clinical diagnostic and prognostic health appraisal tools. 
This novel functionality is underscored by a progressive increase 
in FDA approvals of multiplex proteomic assays for clinical 
use.12 Multiplex immunoassays provide several advantages over 
singleplex immunoassays for obtaining the same cumulative 
information, including enhanced efficiency and reduced cost 
when concurrently measuring multiple analytes from single 
samples, increased throughput, and the mapping of complex 
biochemical networks that may enable developing personalized 
medical interventions.11,12 The relative benefits of multiplex 
protein analysis over singleplex immunoassays are most obvi-
ous with scarce and valuable samples that are restricted in vol-
ume or accessibility, and when streamlining budget, workload, 
and time expenditures are critical concerns.
Multiplex immunoassay platforms have distinct analytical 
performance capabilities, strengths, shortcomings, and instru-
mentation and operator requirements. The current study com-
pared the analytical performance characteristics of 2 different 
commonly used multiplex platforms—a bead-based fluores-
cence assay and a planar chemiluminescence assay—to quan-
tify circulating cytokine concentrations in human plasma 
samples and to assess operator time requirements for assay 
completion. Both methods employed 96-well microtiter plate 
formats and measured 19 common cytokine analytes in identi-
cal samples. Additionally, we performed a time-and-motion 
assessment of both operator-attentive and total time required 
for assay completion with each method. Our group is inter-
ested in identifying and characterizing blood tumor biomark-
ers in brain cancer, and the evaluated plasma samples were 
obtained from patients upon diagnosis of either primary glio-
blastoma or of brain metastases of various cancers originating 
in other organs. Plasma samples from ostensibly healthy sub-
jects were assessed as controls. The purpose of our study was to 
interrogate multiplex methodologies to find the best platform 
to comprehensively characterize circulating cytokine profiles 
for oncological research, and to investigate their potential for 
identifying molecular signatures specific for GBM and for 
brain metastases from other primary sites.
Materials and Methods
Multiplex assay kits and instrumentation
This study compared 2 multiplex immunoassay detection sys-
tems. The bead-based fluorescence assay was the MILLIPLEX® 
MAP Human High Sensitivity T Cell Magnetic Bead Panel 
(Product #HSTCMAG28SMPX21; Merck EMD Millipore, 
Billerica, MA), that simultaneously evaluates 21 analytes (frac-
talkine, GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-21, IL-23, ITAC, 
MIP-1α, MIP-1β, MIP-3α, and TNFα) in suspension.13 This 
assay was run on the Luminex® FLEXMAP 3D® detection 
instrument operated with xPONENT Software V4.2 (both 
from Luminex Corp., Austin, TX). This system has improved 
sensitivity, broader dynamic range, and higher throughput than 
the predecessor Luminex 100/200™ technology used in earlier 
studies.11
The second platform was the electrochemiluminescence-
based Meso Scale Discovery solid-matrix assay (MSD V-Plex® 
kits; Meso Scale Discovery, LLC, Rockville, MD). Because 
the MSD 96-well electrochemiluminescence immunoassay 
kits that we used were limited to assessing 10 cytokines per 
assay, we evaluated identical samples using 4 different kits, 3 
customized, to achieve reasonable overlap with the 21-plex 
LMX assay. The MSD Proinflammatory Panel 1 (Product 
#K15049G) measures IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL 8, 
IL-10, IL-12 (p70), IL-13 and TNF-α). We also purchased 3 
customized kits that measured 3 to 4 relevant molecules each: 
the TH17 V-Plex® (#K15085D) measured IL-21, IL-23, and 
MIP-3α; the Cytokine Panel 1 (#K15050D) measured 
GM-CSF, IL-5, IL-7, and IL-17A; and the Chemokine Panel 
1 (#K15047D) measured IL-8 HA, MIP-1α, and MIP-1β. 
The Quickplex SQ120 detection instrument was operated 
using MSD Discovery workbench software v.3.0/4.0 (both 
from Meso Scale Discovery).14 The Luminex/MILLIPLEX 
and Meso Scale Discovery systems and associated results are 
hereafter abbreviated as “LMX” and “MSD,” respectively.
Together, the LMX and MSD assays measured 19 common 
cytokine analytes: GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, IL-21, 
IL-23, MIP-1α, MIP-1β, MIP-3α, and TNFα. Kits were used 
before their stated expiration dates, and all assay steps were 
performed in accordance with manufacturer instructions.13,14 
With both platforms, samples and accompanying kit standards 
were manually pipetted into assay plates. All samples were 
assayed in duplicate in all kits. The LMX assay used 25 µL of 
sample per duplicate well. The MSD kits used either 12.5 or 
25 µL of sample per duplicate well, depending on the specific 
kit. Thus, the LMX kit required 50 µL of each sample and the 
MSD kits together required 150 µL of each sample to provide 
desired analyte overlap. One key difference is the LMX assay 
requires an overnight sample incubation time whereas the 
MSD offers a standard 2-hour or alternative overnight sample 
incubation. This experimental series used the manufacturer-
preferred 2-hour incubation period for the MSD kits. Washing 
steps for the LMX assay were performed using an automated 
programmable washer-dispenser (BioTek MultiFlow FX rea-
gent dispenser and BioTek 405 TS Microplate Washer (both 
from BioTek, Winooski, VT). Reagents dispensation and plate 
washing for the MSD assays were manually performed using a 
multichannel pipettor.
Samples
Plasma samples were centrifugally separated from venous 
blood samples drawn into EDTA-anticoagulant collection 
tubes and stored at −80°C until analysis by both assays, having 
undergone only a single freeze-thaw event. Demographic 
information on sample donors is provided in Table 1. Subjects 
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included 27 persons diagnosed with glioblastoma (GBM) and 
17 persons with brain metastases (BrMet) from primary lung, 
breast, or melanoma primary tumors. Plasma samples from 11 
anonymous healthy control (HC) individuals were purchased 
from Discovery Life Sciences (Los Osos, CA). This study was 
performed under the approval and oversight of the Washington 
University Institutional Review Board. All volunteers provided 
written informed consent prior to enrollment and sample pro-
vision. Study performance complied with the tenets of the 
Declaration of Helsinki.
Experimental overview
Prior to analysis, all samples were thawed on ice and centri-
fuged at 15 000 × g for 10 minute at 4°C to remove potential 
particulates. In all instances, samples were run in duplicate and 
each assay plate contained recombinant standards for each ana-
lyte and quality control (QC) samples provided with the kits. 
Calibration curves were established according to the user man-
uals using serial 4-fold dilutions of each kit’s stock analyte 
standards. Blank values were established using the sample dilu-
ent supplied with each immunoassay kit. All samples were 
diluted 1:2 or 1:4 using the sample diluent provided in each kit.
Assay performance characteristics
We assessed intra-assay precision, the lower and upper limits of 
quantification (LLoQ and ULoQ, respectively), and the result-
ing dynamic ranges of cytokine detection for both assays.15,16 
The mean of 8 blank values measured on LMX and MSD 
plates were used to calculate the LLoQ, defined as the mean 
blank signal + 2.5 × SD. The ULoQ was defined as the high-
est mean standard curve value for each analyte in each kit.
Comparative evaluation of cytokine levels in 
human plasma
We measured the circulating concentrations of 19 cytokines 
in diverse plasma samples from the 3 subject groups (GBM, 
BrMet, HC) using both platforms, and evaluated whether val-
ues for any analyte were outside of the assays’ dynamic range of 
quantification. Bland-Altman correlation plots were generated 
to assess cytokine measurement agreement between LMX and 
MSD.17
Time and motion study
We evaluated and compared the precise time allocations 
required for labor (operator hands-on and/or mandatory obser-
vation) and total times including incubations to evaluate a 
similar number of analytes by both assay methods. All assays 
were performed by the same technician. Observation and tim-
ing data collection were conducted by Nexus (Plano, TX), an 
independent third-party healthcare consulting firm.
Data analysis
Data were analyzed using Prism v.8 graphing and statistical 
analysis software (GraphPad Software, Inc., San Diego, CA), 
and Excel v.16 (Microsoft Inc. Redmond). Analyte concentra-
tions were determined by comparing sample readings to stand-
ard curves generated using a 4-parameter logistical curve fit 
algorithm (Belysa v.1 software from Millipore/Sigma for 
LMX, and MSD Discovery v.3.0/4.0 for MSD. Analyte con-
centrations are presented as pg/mL ± SD, range, or as number 
(% of samples), as appropriate. Means were compared by one-
way ANOVA, followed by Tukey test for multiple comparisons. 
Proportions of samples within the dynamic range were com-
pared for each analyte using the Fisher Exact test. Bland-
Altman correlation plots show the mean ratios of MSD/LMX 
concentrations detected for each analyte within each sample, 
and include 95% limit-of-agreement representing mean values 
±1.96 × SD. Any mean slope deviation from 1 was indicative 
of proportional (concentration-dependent) bias in 1 or both 
assays for that analyte.
Results
Analytical limits of detection and quantif ication, 
and dynamic range
The dynamic range was defined as the spread between the cal-
culated LLoQ and the mean measured value of the highest 
standard curve point (ULoQ), and was determined for all 22 
analytes coordinately and individually measured by the LMX 
and MSD systems. The dynamic ranges of quantification for 
all 22 combined cytokine analytes that both assay platforms 
measured are tabulated in Table 2, with the ranges of the 19 
shared analytes shown graphically in Figure 1. Dynamic ranges 
for all analytes in both assays were within the expected ranges 
Table 1. Demographics of plasma donors.
PARAMETER GBM BRMET HC
n 27 17 11
Gender, male/female, n 14/13 4/13 1/10
Age, y, mean ± SD 56.7 ± 12.7 59.0 ± 13.2 35.1 ± 7.8
Age, y, range 25-82 31-81 26-47
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stated in assay lot-specific documentation. The MSD platform 
had lower analytical LLoQs than LMX for 17 of 19 (89%) 
shared cytokines. For IFN-γ, the LLoQ with LMX was 66% of 
the MSD value, and for both IL-8 and IL-21, the LMX values 
were 50% of LLoQs obtained using the MSD assay. The LMX 
assay had higher ULoQs for 17 of 19 (89%) analytes, ranging 
from 6% higher for MIP-1α to a maximal 3810% higher for 
IL-4. In 2 analytes, IL-17A and IL-21, the ULoQs deter-
mined by LMX were 55% and 66% of the ULoQ measure-
ments obtained with the MSD assay, respectively.
For 14 of 19 (74%) shared analytes, the MSD dynamic 
range was larger than that of the LMX platforms; in the 
remaining 5 instances (IFN-γ, IL-13, IL-21, MIP-1β, and 
TNF-α), the LMX range breadth was between 32% and 419% 
larger than the MSD range size (Table 2). Only in 2 analytes 
(IL-5 and IL-10) were the LMX and MSD dynamic range 
magnitudes within 20% of each other. In 2 instances (IL-4 and 
IL-10), the differences in both upper and lower quantification 
levels differed by at least an order of magnitude between the 2 
assays.
Proportion of samples within assay quantif ication 
range
A total of 55 plasma samples from all 3 experimental groups 
were evaluated in duplicate wells using both platforms 
(Figure 2). With the LMX system, all of the 19 shared 
cytokines were quantifiable in 100% of samples tested. Despite 
Table 2. Limits of quantitation and dynamic range of analytes measured by the bead-based fluorescence (LMX) and planar 
electrochemiluminescence (MSD) multiplex assays. Dynamic range spans the lower limit of quantitation (LLoQ) and upper limit of quantitation.
19 SHARED 
ANALyTES








DyNAMIC RANGE SIZE 
(FOLD OF LLOQ)
GM-CSF 0.90-18 629 20 699 0.05-4393 87 860 0.23
IFN-γ 0.19-9639 50 731 0.29-4745 16 362 3.10
IL-1β 0.21-7315 34 833 0.03-1791 59 700 0.58
IL-2 0.20-7633 38 165 0.07-5401 77 157 0.49
IL-4 1.49-28 992 19 458 0.01-761 76 100 0.26
IL-5 0.20-7581 37 905 0.08-3465 43 312 0.87
IL-6 0.66-2912 4412 0.04-2524 63 100 0.07
IL-7 3.62-5717 1579 0.06-3397 56 617 0.03
IL-8 0.10-4795 47 950 0.02-2277 113 850 0.42
IL-10 1.21-23 291 19 249 0.08-1806 22 575 0.85
IL-12 p70 0.27-7909 29 293 0.03-2217 73 900 0.40
IL-13 0.20-3913 19 565 0.11-1574 14 309 1.37
IL-17A 1.78-11 391 6399 0.23-20 872 90 748 0.07
IL-21 0.11-3818 34 709 0.22-5786 26 300 1.32
IL-23 12.15-124 034 10 208 0.22-20 833 94 695 0.11
MIP-1α 5.58-4604 825 1.17-4345 3714 0.22
MIP-1β 0.57-14 808 25 979 0.30-3528 11 760 2.21
MIP-3α 0.60-9400 15 667 0.08-1806 22 575 0.69








Fractalkine 19.38-285 596 14 737 n/a n/a n/a
ITAC 1.58-22 425 14 193 n/a n/a n/a
IL-8 HA n/a n/a 109-239 574 2198 ‒
“n/a” indicates “not applicable” because that particular analyte was not included in the platform.
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having a lower LLoQ for a plurality of common analytes, in 
many instances the MSD chemiluminescence assay was unable 
to detect these cytokines in human plasma samples. All 
instances where experimental values fell outside of an analyte’s 
dynamic range were with readings below the LLoQ; no value 
ever exceeded the ULoQ for any analyte. The MSD platform 
detected and quantified 7 of 19 analytes (37%) in 100% of sam-
ples (ie, IL-6, IL-7, IL-8, IL-10, MIP-1β, MIP-3α, and 
TNF-α). The MSD assay detection/quantification rate for 
MIP-1α, IL-12p70, IL-1β, IL-17A, and IFN-γ in samples 
was 96%, 90%, 86%, 76%, and 75%, respectively. The MSD 
detection rate was <75% for the remaining 7 of 19 (37%) ana-
lytes, including a 0% detection rate for IL-21 and a 8% detec-
tion rate for IL-23. By contrast, the LMX system detected and 
quantified valid concentrations of IL-21 (range 1.8-18.9 pg/
mL) and IL-23 (range 86.8-1922.2 pg/mL) in all samples. 
Using Fisher Exact test, 11/19 analytes were missed at a sig-
nificantly greater frequency in samples using MSD versus 
LMX (Figure 2).
Analyte concentrations according to assay platform
All 19 shared cytokine analytes were evaluated in 55 human 
plasma samples comprising 27 glioma subjects, 17 subjects 
with secondary brain metastases, and 11 controls (Figure 3 and 
Table 3). The LMX platform categorized identical samples at 
significantly greater concentrations than did the MSD system 
for most analytes. Clear differences occurred with IL-4, 
whereby LMX categorized cytokine concentrations at 4 orders 
of magnitude higher than did MSD, and GM-CSF at 2 to 3 
orders of magnitude greater than MSD values. Notably, when 
the MSD platform evaluated IL-21, although the analyte 
quantification limit on standard curves was 0.22 pg/mL, no 
cytokine was detectable in any sample; the LMX platform, 
however, returned values in all of the identical samples, ranging 
from 1.8 to 18.9 pg/mL. Another prominent discrepancy 
between assay detection performance occurred with IL-23, 
which displayed a LLoQ that was 55-fold more sensitive with 
MSD (0.22 pg/mL) than LMX (12.15 pg/mL). While IL-23 
was quantifiable by LMX in 100% of samples, the MSD assay 
Figure 1. Dynamic ranges of the Luminex bead-based fluorescence 
(LMX) and Meso Scale Discovery electrochemiluminescence (MSD) 
multiplex cytokine immunoassay kits. Ranges of quantification were 
determined on standard calibration curves. With 3 exceptions (ie, IFN-γ, 
IL-8, and IL-21), the low-end of the remaining 16/19 shared analytes’ 
dynamic ranges was lower with the MSD platform compared to the LMX 
assay. Conversely, and with 2 exceptions (ie, IL-17A and IL-21), the 
high-end of the dynamic range was greater with the LMX assay versus 
the MSD assay. In 2 instances (IL-4 and IL-10), the differences in both 
upper and lower quantification levels differed by at least an order of 
magnitude between the 2 assays.
Figure 2. Proportion of donor plasma samples inside the assay quantification range for the Luminex (LMX) and Meso Scale Discovery (MSD) multiplex 
cytokine immunoassay kits. With the LMX system, all of the 19 shared cytokines were quantifiable in 100% of samples tested. Although the MSD assay 
had a LLoQ below that of the LMX assay for 17/19 (89) common analytes in earlier standard curve performance evaluations, this sensitivity did not directly 
translate to evaluating cytokines in human plasma samples. The MSD platform detected and quantified 7 of 19 analytes (37%) in 100% of plasma 
samples. The MSD assay detection/quantification rate for MIP-1α, IL-12p70, IL-1β, IL-17A, and IFN-γ in samples was 96%, 90%, 86%, 76%, and 75%, 
respectively. The MSD detection rate was <75% in the remaining 7 of 19 (37%) analytes, including a 0% detection rate for IL-21 and a 8% detection rate 
for IL-23.
Asterisks indicate significant differences for 11/19 analytes between MSD and LMX by Fisher Exact test, with “*” indicating P < .05, “**” indicating P < .01, and “***” 
indicating P < .001. No asterisk indicates mathematically similar detection frequencies between platforms for those cytokines.
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Figure 3. Cytokine concentrations in human plasma samples. All 19 shared cytokine analytes were evaluated in 55 human plasma samples comprising 27 
glioma subjects, 17 subjects with secondary brain metastases (BrMet), and 11 healthy controls (HC). Values shown are mean concentration ± SD. The 
Luminex (LMX) platform categorized identical samples at greater concentrations than the Meso Scale Discovery (MSD) system for most analytes. With IL-4, 
wherein LMX categorized cytokine concentrations at 4 orders of magnitude higher than MSD, and GM-CSF values at 2-3 orders of magnitude greater than 
MSD values. Notably, with IL-21, although the MSD lower quantification limit was 0.22 pg/mL, none was detectable by MSD in any sample. The LMX 
platform identified IL-21 in all samples (range 1.8-18.9 pg/mL). With IL-23, the LLoQ was 55-fold more sensitive using MSD (0.22 pg/mL) than LMX (12.15 pg/
mL). While IL-23 was quantifiable by LMX in all samples, MSD detected the analyte in only 8% of samples, and categorized them at lower concentrations 
(range 0.24-2.03 pg/mL) than LMX (range 86.8-1922.2 pg/mL). The MSD platform quantified 7 cytokines in 100% of samples (IL-6, IL-7, IL-8, IL-10, MIP-1β, 
MIP-3α, and TNF-α), and expression trends of each of these across the 3 experimental groups were generally similar between MSD and LMX. With MSD, 
IL-7 levels appeared lower in HC samples versus GBM and BrMet, which was not observed with LMX assessment. While IL-17A was detected in 100% of 
samples by LMX and 76% by MSD, there a contradictory trend appeared in which IL-17 was lower in HC versus the 2 neoplasm groups with LMX, but higher 
with MSD. Only MIP-1β levels were categorized as greater using MSD (range 16.06-166.88 pg/mL) versus LMX (range 4.26-19.65 pg/mL).
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detected the analyte in only 8% of the same samples, and cat-
egorized them at a much lower concentration (range 0.35-
2.03 pg/mL) than did LMX (range 86.8-1922.2 pg/mL).
Of the 7 analytes in which the MSD platform detected 
quantifiable cytokine in 100% of samples (ie, IL-6, IL-7, IL-8, 
IL-10, MIP-1β, MIP-3α, and TNF-α), the trends in relative 
expression levels of these cytokines across the 3 experimental 
groups were similar between MSD and LMX in most instances. 
With MSD, values for IL-7 appeared lower in the HC samples 
versus GBM and BrMet samples, which was not observed with 
LMX assessment. With IL-17A, which was detected in 100% 
of samples by LMX and 76% of samples by MSD, there 
appeared to be a contradictory trend in which IL-17A was 
lower in HC plasma versus the 2 neoplasm samples with LMX, 
but higher with MSD. A similarly contrary relationship regard-
ing IL-5 concentration in controls versus neoplasm groups was 
observed.
In a single instance, MIP-1β, cytokine levels quantified by 
MSD (range 16.06-166.88 pg/mL) were greater than concen-
trations determined by LMX (range 4.26-19.65 pg/mL), and 
the relative expression level relationships across the 3 experi-
mental groups appeared similar with both MSD and LMX.
Cytokine profiles in healthy, GBM, and BrMet 
plasma
Because of the high frequency of non-quantifiable target 
cytokines using the MSD platform, we limited our analysis of 
patient versus HC to LMX findings, with which all analytes 
were detectable in all samples, although MSD findings are pro-
vided in Supplemental Table 1. Concentrations of multiple 
cytokines including GM-CSF, IFN-γ, IL-1β, IL-5, IL-10, 
IL-17A, IL-21, IL-23, MIP-1α, and MIP-3α were signifi-
cantly elevated in GBM plasma compared to HC (Table 3). Of 
Table 3. Cytokine levels measured by a bead-based fluorescence multiplex assay in plasma samples from healthy controls (HC; n = 11), subjects 
with secondary brain metastases from other organs (BrMet; n = 17), and individuals with glioblastoma (GBM; n = 27).








% OF HC P-VALUE 
VS HC
GM-CSF 16.8 ± 5.1 31.6 ± 13.9 188 .011 31.2 ± 13.0 186 .008
IFN-γ 10.8 ± 3.5 17.5 ± 6.2 162 .037 20.0 ± 8.0 185 .0012
IL-1β 1.1 ± 0.4 2.1 ± 0.9 191 .026 2.6 ± 1.0 236 .0001
IL-2 4.7 ± 2.0 6.8 ± 2.8 145 ns 4.8 ± 2.3 102 ns
IL-4 61.7 ± 16.2 111.1 ± 47.9 180 .003 66.9 ± 32.1 108 ns
IL-5 5.2 ± 1.6 11.5 ± 4.5 221 .005 13.0 ± 5.6 250 .0002
IL-6 7.3 ± 2.6 12.9 ± 6.3 178 .004 6.3 ± 2.6 86 ns
IL-7 18.0 ± 5.5 27.8 ± 6.8 154 <.001 17.6 ± 4.6 98 ns
IL-8 10.4 ± 5.6 12.7 ± 8.8 122 ns 7.3 ± 3.6 70 ns
IL-10 20.4 ± 10.8 69.7 ± 25.4 293 <.0001 71.2 ± 31.1 286 <.0001
IL-12 p70 4.1 ± 1.8 5.9 ± 2.2 143 ns 5.5 ± 1.9 134 ns
IL-13 10.3 ± 5.3 15.6 ± 7.4 151 .039 7.1 ± 3.3 69 ns
IL-17A 12.1 ± 3.3 19.0 ± 7.4 157 ns 19.3 ± 8.8 159 .028
IL-21 4.9 ± 2.9 10.1 ± 4.9 206 .005 8.8 ± 3.9 180 .029
IL-23 356 ± 290 394 ± 171 111 ns 792 ± 435 222 .004
MIP-1α 29.4 ± 3.9 40.2 ± 6.9 137 .0008 36.1 ± 7.7 123 .030
MIP-1β 8.4 ± 3.3 9.2 ± 4.1 109 ns 10.0 ± 3.7 119 ns
MIP-3α 15.2 ± 9.1 14.9 ± 4.1 98 ns 20.8 ± 6.3 137 .045
TNF-α 5.9 ± 2.3 4.2 ± 1.9 72 ns 6.0 ± 2.1 102 ns
Concentrations are shown as mean pg/mL ± SD. P-values were determined by one-way ANOVA adjusted for multiple comparisons using Tukey test. Bolded values 
indicate statistically significant differences from HC. Differences from HC that are not significant are labeled “ns”.
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these analytes, measured values were at least double in GBM 
versus HC for 4, comprising IL-1β, IL-5, IL-10, and IL-23; 
levels for GM-CSF (186%), IFN-γ (185%), and IL-21 (180%) 
were very close to double in GBM versus HC plasma. Values of 
cytokines measured in BrMet samples are shown in Figure 3 
and Table 3. Cytokines that were commonly elevated in GBM 
and BrMet plasma versus controls included GM-CSF, IFN-γ, 
IL-1β, IL-5, IL-10, IL-21, and MIP-1α. Analytes that were 
uniquely upregulated in GBM but not BrMet plasma included 
IL-17. IL-23 and MIP-3α, all of which have inflammatory 
functions and suspected roles in tumorigenesis.18-20 Analytes 
that were uniquely elevated in BrMet but not GBM samples 
compared to controls were the classical Th2 cytokines IL-4, 
IL-6 and IL-13,21and IL-7, a promoter of both T- and B-cell 
development.22 Interpretation of the significance of the various 
analytes measured in BrMet plasma is confounded because 
patients had received some type of chemotherapy regimen for 
their non-brain primary tumor that likely affected cytokine 
expression.
Correlation analysis
Correlations between LMX and MSD assay categorization of 
levels of the 19 shared analytes measured in human plasma 
were graphed on Bland-Altman plots (Figure 4).17 Log2 values 
of the mean MSD/LMX analyte concentration ratios shown 
on the y-axis estimates systematic bias. Good correlation is 
assumed between assays if the mean value approximates zero 
deviation. The 95% limits of agreement lines represent 
±1.96 SDs from the mean. For most shared analytes, the mean 
concentration ratio was shifted from zero to a positive value, 
indicating that LMX classified the target cytokine in the same 
plasma samples at a higher concentration than MSD. The sole 
exception was with MIP-1β, where MSD characterized sam-
ples as containing markedly higher concentrations of cytokine 
than LMX. Analyte-concentration-dependent effects (ie, pro-
portional bias) were suggested by the slope of the mean line, 
and were particularly notable for IL-7 and MIP-1β. The only 
native cytokine whose concentration was characterized nearly 
identically by both assays was IL-8. Interpretation of these data 
becomes less certain when SDs are large and 95% limits of 
agreement are spread further apart, reflective of widely distrib-
uted data points away from the mean. The maximum mean 
differences were restricted to −200 or +200 due to software 
limitations, but can theoretically be larger. In the case of IL-21, 
no cytokine was identified within the MSD assay’s dynamic 
range of quantitation in any sample; hence, the true mean dif-
ference is not 200, but infinity.
Time in motion study
Hands-on labor time was 1 hour 38 minutes for LMX and 
2 hours 42 minutes for the MSD assays, reflecting the increased 
number of MSD plates required. The total time required for 
performing the single Luminex (LMX) 21-plex and 4 Meso 
Scale Discovery (MSD) 3- to 10-plex assays was approximately 
21.1 hours and 6.2 hours, respectively. This included a proto-
col-specified overnight primary antibody/sample incubation 
for LMX, and a 2-hour primary antibody/sample incubation 
for MSD (the alternative manufacturer-allowed overnight 
incubation was not used).
Discussion
Cytokines are critical mediators of diverse disease states, and 
have multiple pleotropic actions in different organs.3,4 Earlier 
categorization of inflammatory and anti-inflammatory 
cytokine categories has been revised with the appreciation that 
cytokines function in complex interacting pathways, often 
regulate the expression of other cytokines, and their inflam-
matory or anti-inflammatory roles depending upon their envi-
ronmental context.23,24 Understanding the function of complex 
cytokine networks in pathogenesis requires comparison of 
expression profiles of multiple cytokines in health and disease 
states.25 Cytokines can serve as molecular biomarkers that 
provide insight into the development, progression, and prog-
nosis of both acute health threats such as sepsis26 and trauma,27 
and of chronic disorders including, for example, autoimmune,28 
cardiopulmonary,29,30 and neoplastic diseases.5
Glioblastoma and brain metastases are particularly lethal 
neoplastic disorders with limited treatment options,1,2 whose 
pathogenesis may be modulated by multiple cytokines.6-10 
Cytokines play important roles in immune cell infiltration and 
function. Although the brain is generally an immunologically 
specialized site, immune cell infiltration occurs in GBM tissue, 
with macrophages/microglial cells comprising a significant 
proportion of the tumor mass.31,32 We hypothesized that 
cytokines released from the GBM or brain metastatic tissues, 
and from immune cells in the tumor microenvironment, can be 
non-invasively identified in the circulation. These unique 
molecular profiles might provide information on disease exist-
ence, type, responsiveness to treatment, and prognosis. We 
evaluated these hypothesized biomarker signatures using mul-
tiplex proteomic immunoassays.
Multiplex assays have advantages over classical singleplex 
colorimetric ELISAs in that they simultaneously quantify 
numerous bioactive molecules within a single small sample 
volume to give a more complete overview of circulating 
analytes.12,33,34 Multiplex immunoanalysis streamlines cytokine 
profiling with improved productivity, while decreasing finan-
cial, time, and personnel expenditures needed to evaluate many 
analytes individually.12,15,16 These benefits are particularly valu-
able when evaluating diverse cytokines in rare or size-limited 
samples.
To identify potential circulating GBM-associated biomark-
ers, we compared concentrations of 19 cytokines in plasma from 
newly-diagnosed GBM patients and healthy individuals, using 
2 different multiplex immunoassay platforms.13,14 The dynamic 
range of fluorescence and electrochemiluminescence multiplex 
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immunoassays is generally several orders of magnitude greater 
than that of singleplex ELISAs.12,33,34 In our study, the MSD 
platform calibration curves suggested superior sensitivity than 
the LMX assay, with lower LLoQs for 89% of analytes, having 
12 of 19 analytes’ LLoQ registering below 100 fg/mL. With 
native proteins in plasma samples, however, the MSD assay was 
surprisingly unable, in our hands, to detect or quantify many 
cytokines that LMX assessed in the 1 to 100 pg/mL range. This 
incongruous analyte classification was confirmed by correlation 
analyses. An example of this disparity was IL-21, which LMX 
quantified in all 55 of 55 samples (range 1.8-18.9 pg/mL) but 
was not detected by MSD in any sample even though MSD 
calibrator curves indicated a LLoQ of 0.22 pg/mL. Although 
many parameters can affect multiplex immunoassay function, 
we speculate that, while the MSD assay is excellent at quantify-
ing the kit-specific recombinant cytokine fragments used for 
Figure 4. Correlation analysis of concentrations of the 19 cytokines measured in 27 human plasma samples from patients with glioblastoma by the 
Luminex (LMX) and Meso Scale Discovery (MSD) multiplex assays. Log2 values of MSD/LMX concentration ratios are shown on the y-axis, and estimate 
systematic measurement differences between methods when the mean value deviates from zero. A negative shift of the blue mean indicates that the MSD 
assay classifies the analyte at concentrations lower than LMX, and vice versa. The red ±1.96 SD lines represent 95% limits of agreement, and when SDs 
are large or n-values are low, then interpretation can be ambiguous. For 17 of 19 shared analytes, the mean concentration ratio was shifted to a positive 
value, indicating that LMX classified the target cytokine in identical plasma samples at a higher concentration than MSD. The sole exception was with 
MIP-1β, where MSD characterized samples as containing markedly higher concentrations of cytokine than LMX. Analyte-concentration-dependent effects 
were suggested by the slope of the mean line, and were notable for IL-7 and MIP-1β. The only cytokine similarly characterized by both assays was IL-8.
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calibration, it may be less efficient in detecting native proteins, 
at least in the sample types/collection media we tested. While 
this manuscript was in preparation, another publication reported 
similar findings in which MSD missed detection of considera-
bly more overlapping cytokine analytes in 62 (similarly EDTA-
anticoagulated) human plasma samples than simultaneously 
performed LMX assays.35 Hands-on time required for LMX 
assessment was only 60% of vigilant time required with MSD 
because we needed to use 4 MSD plates to obtain desired ana-
lyte overlap with a single LMX 21-plex kit. Although assay 
time determinations were only performed once per platform in 
this study, our findings concur well with another report in which 
hands-on labor time to assay 16 overlapping cytokines in human 
plasma was reduced by 36% using LMX (1 hour 37 minutes) 
compared to the MSD platform (2 hour 33 minutes).35 Given 
the frequency of undetected analytes in samples with the MSD 
platform, we focused on assessing results obtained using the 
LMX assay.
Multiple cytokines were upregulated in the plasma of GBM 
and/or BrMet subjects compared to circulating levels in healthy 
volunteers. In GBM plasma, we identified significant elevation 
of 10 of 19 evaluated cytokines versus control samples, com-
prising GM-CSF, IFN-γ, IL-1β, IL-5, IL-10, IL-17A, IL-21, 
IL-23, MIP-1α, and MIP-3α. Of these analytes, measured 
values were at least double in GBM versus HC for 4, compris-
ing IL-1β, IL-5, IL-10, and IL-23; concentrations were nearly 
double in GBM samples for GM-CSF, IFN-γ, and IL-21. 
Cytokines that were commonly elevated in GBM and BrMet 
plasma versus healthy control samples were GM-CSF, IFN-γ, 
IL-1β, IL-5, IL-10, IL-21, and MIP-1α. Analytes uniquely 
upregulated in GBM but not BrMet plasma included IL-17A, 
IL-23, and MIP-3α, all of which have inflammatory activity 
and are suspected to play proliferative and/or metastatic roles 
in solid tumors including glioblastoma.18-20 Analytes uniquely 
elevated in BrMet but not GBM plasma versus controls were 
IL-4, IL-6, IL-7, IL-10, IL-13, and MIP-3α. Besides IL-5, 
classical Th2 cytokines (ie, IL-4, IL-10, and IL 13) were nota-
bly elevated in BrMet but not GBM samples compared to 
healthy control plasma. Cytokines that were commonly ele-
vated in GBM and BrMet plasma versus controls included 
GM-CSF, IFN-γ, IL-1β, IL-5, IL-10, IL-21, and MIP-1α. 
Analytes that were uniquely upregulated in GBM but not 
BrMet plasma included IL-17A and IL-23, both associated 
with glioblastoma progression,18,19 and MIP-3α (chemokine 
CCL20), which is an inflammatory chemokine with known 
roles in solid tumor progression and metastasis.20 MIP-3α 
contributes to the progression of liver, colon, breast, pancreatic, 
and gastric cancers.36 In glioblastoma, MIP-3α released from 
neighboring astrocytes may enhance malignancy by inducing 
hypoxia-induced factor-1 (HIF-1) expression in tumor cells, 
thereby promoting their survival and functionality in the 
hypoxic tumor environment.37
Analytes that were uniquely elevated in BrMet but not 
GBM samples compared to controls were the classical Th2 
cytokines IL-4, IL-6, and IL-13,21 and IL-7, a promoter of 
both T- and B-cell development22 that is also a prognostic bio-
marker of improved survival in malignant glioblastoma.38 
However, BrMet samples came from individuals who had vari-
able histories of receiving chemotherapy for their primary non-
brain tumors, which can induce cytokine expression,39 thereby 
confounding meaningful comparison with GBM findings. All 
GBM samples were obtained at the time of initial diagnosis 
from individuals who were treatment naïve, so cytokines dif-
ferentially expressed in GBM plasma might be part of a valid 
GBM-specific biomarker profile.
A similar study used bead-based immunoassays to profile 
48 circulating cytokine levels, and identified an 18-cytokine 
signature that discriminated 26 healthy subjects from 148 
GBM patients with a diagnostic accuracy of 95.40%.40 Of the 
18 markers detected by those researchers, 5 shared cytokines 
were similarly upregulated in GBM in our study: GM-CSF, 
IFN-γ, IL-12, IL-17A, and MIP-1α. When we queried the 
US National Cancer Institute’s Cancer Genome Atlas 
(TCGA) microarray database (available at https://portal.gdc.
cancer.gov/projects/TCGA-GBM), both GM-CSF and 
IFN-γ showed increased transcript levels in GBM versus nor-
mal brain tissues, suggesting the tumor tissue itself as a pri-
mary source of these 2 circulating analytes. Conversely, 
IL-17A was upregulated in GBM plasma by our protein anal-
ysis compared to control plasma, although transcript levels of 
IL-17A were decreased in GBM tissue versus normal brain 
tissue in the TCGA database. This suggests that cells extrane-
ous to the primary tumor mass are responsible for the increased 
circulating IL-17A that we detected in GBM plasma, but that 
these biomarkers, together with others, might provide a 
cytokine profile specific to GBM.
By univariate and multivariate cox regression survival 
analyses, the earlier group determined that out of their iden-
tified 18-cytokine GBM signature, only IL-17A and IL-4 
had good prognostic value.40 We identified a 1.7-fold 
increase in plasma IL-17A levels in GBM versus healthy 
subjects, but did not identify a difference in circulating IL-4 
concentrations. Greater numbers of T helper type 17 (Th17) 
cells in gliomas are associated with higher number of mye-
loid (CD11b) cells as well as the expression of TGF-β1 and 
IL-6,41 though we saw no change in IL-6 and did not meas-
ure TGF-β1. IL-1β and IL-23, both of which we observed 
to be elevated in GBM plasma, are critical in inducing the 
Th17 phenotype in humans.42,43 Glioma-associated Th17 
cells are potentially non-cytotoxic and may contribute to 
immune suppression,41 and thereby disease progression. 
Ultimately, the collective pattern of expression of these mol-
ecules might serve as a useful clinical biomarker signature 
for detecting GBM and tracking progression. There may be 
similar utility for cytokine signatures in patients with brain 
metastases, although it is not surprising that the composi-
tion of cytokines detected may differ if systemic disease bur-
den is variable.
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Our findings support the discoveries of other researchers 
toward identifying a GBM-specific circulating cytokine pro-
file. Differences between our findings and those from a previ-
ous large cytokine profiling study40 may have resulted from 
sampling differences, whereby we tested plasma from blood 
collected in EDTA-anticoagulant solution and immediately 
centrifuged then frozen, while the prior study collected sera 
from whole blood specimens that were separated after allowing 
sample coagulation overnight at 4°C before freezer storage. 
Future studies will ascertain whether tightly-coordinated sam-
pling and assay parameter selection can produce more congru-
ity in establishing a definitive and prognostic GBM cytokine 
biomarker signature. Additional work will be needed to deter-
mine how these cytokines change through the course of a 
patient’s disease and whether cytokine expression in cerebro-
spinal fluid may also yield important insights. Future experi-
ments should evaluate additional molecules with known or 
suspected prognostic value in assessing GBM. It will be impor-
tant to establish cytokine baselines at diagnosis, as reported 
here, and then follow longitudinally how expression may 
change throughout treatment, particularly with the increasing 
interest in immunotherapy. Limitations of this study include 
the relatively low number of GBM samples available for test-
ing and the limited number of cytokines evaluated. We recog-
nize that the complexities of multiplex proteomic immunoassay 
procedures will require extensive validation before being 
acceptable for clinical use. Ideally, all findings would be repeat-
able with the same samples using simplex immunoassays 
employing the exact same reference cytokines used in the mul-
tiplex platform. Nonetheless, this study demonstrated that 
appropriate multiplex platforms have important utility for dis-
secting the complex molecular mechanisms that drive the 
pathology of diverse health disorders, including GBM and 
metastatic cancers.
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